Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) 31.3% HIGHER; Bayer HealthCare Pharmaceuticals and Onyx Pharma today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival.
The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Click here to see the full report.
Media General, Inc. (NYSE: MEG) 29.8% HIGHER; reports Q2 EPS from continuing...
Post new comment